Skip to main content
Back
Watch Compare

AN2 Therapeutics, Inc.

Data quality: 83%
ANTX
Nasdaq Manufacturing Chemicals
$3.25
▼ $0.09 (-2.69%)
Mkt Cap: 116.81 M
Price
$3.25
Mkt Cap
116.81 M
Day Range
$3.20 — $3.35
52-Week Range
$1.00 — $6.91
Volume
119,774
Open $3.32
50D / 200D Avg
$2.39
36.24% above
50D / 200D Avg
$1.46
122.19% above

Quick Summary

Key Takeaways

Negative free cash flow of -29.83 M

Growth

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Quality

Return on Equity
-54.44%
Below sector avg (-53.41%)
ROIC-42.09%
Net MarginN/A
Op. MarginN/A

Safety

Debt / Equity
N/A
Current RatioN/A
Interest CoverageN/A

Valuation

PE (TTM)
-3.32
Below sector avg (-1.48)
P/B Ratio1.93
EV/EBITDAN/A
Dividend YieldN/A

Price History

Financial Trends

Peer Comparison

vs Manufacturing sector median (1364 peers)
Metric Stock Sector Median
P/E -3.3 -1.5
P/B 1.9 1.6
ROE % -54.4 -53.4
Net Margin % — -41.5
Rev Growth 5Y % — 1.8
D/E — 0.3

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -35.17 M
ROE -54.44% ROA -49.17%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -29.83 M
ROIC -42.09% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio N/A
Interest Coverage N/A Asset Turnover N/A
Working Capital N/A Tangible Book Value 60.38 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -3.32 Forward P/E N/A
P/B Ratio 1.93 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -25.54%
Market Cap 116.81 M Enterprise Value 98.81 M
Per Share
EPS (Diluted TTM) -1.16 Revenue / Share N/A
FCF / Share -0.83 OCF / Share -0.83
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 84.82%
SBC-Adj. FCF -36.58 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022
Revenue — — — —
Net Income -35.17 M -51.32 M -64.73 M -40.96 M
EPS (Diluted) -1.16 -1.72 -2.74 -2.79
Gross Profit — — — —
Operating Income -38.11 M -56.79 M -69.64 M -42.26 M
EBITDA — — — —
R&D Expenses 24.77 M 40.49 M 54.87 M 28.51 M
SG&A Expenses — — — —
D&A — — — —
Interest Expense — — — —
Income Tax 0.0 0.0 0.0 0.0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022
Total Assets 61.95 M 92.09 M 138.74 M 102.56 M
Total Liabilities 8.89 M 10.24 M 14.04 M 7.19 M
Shareholders' Equity 53.06 M 81.85 M 124.70 M 95.37 M
Total Debt — — — —
Cash & Equivalents 19.94 M 21.35 M 15.65 M 27.22 M
Current Assets 59.94 M 86.26 M 110.51 M 98.62 M
Current Liabilities 8.72 M — 14.04 M 7.19 M